1. Home
  2. INDP vs MNDR Comparison

INDP vs MNDR Comparison

Compare INDP & MNDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.41

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Logo Mobile-health Network Solutions Class A Ordinary Shares

MNDR

Mobile-health Network Solutions Class A Ordinary Shares

HOLD

Current Price

$0.91

Market Cap

4.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
INDP
MNDR
Founded
2000
2016
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2M
4.4M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
INDP
MNDR
Price
$2.41
$0.91
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
67.1K
318.3K
Earning Date
05-11-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$608,852.40
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.66
52 Week High
$13.24
$5.42

Technical Indicators

Market Signals
Indicator
INDP
MNDR
Relative Strength Index (RSI) 45.22 58.30
Support Level $2.36 $0.79
Resistance Level $3.11 $1.00
Average True Range (ATR) 0.41 0.09
MACD -0.07 0.01
Stochastic Oscillator 25.71 73.97

Price Performance

Historical Comparison
INDP
MNDR

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

About MNDR Mobile-health Network Solutions Class A Ordinary Shares

Mobile-health Network Solutions is a company engaged in providing telehealth solutions in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application. It provides services on its MaNaDr platform, which is accessible via mobile application and website. The MaNaDr platform is a platform designed and created by doctors, for doctors and users, equipped with services like consultations with doctors, e-commerce pharma store, and others. The company's operating segments are Telemedicine and other services, and the Sale of medicine and medical devices. The majority of the company's revenue is derived from the Telemedicine and other services segment. Geographically, it derives revenue from Singapore.

Share on Social Networks: